| home > About Us # About Us Lexicon Genetics is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. We are systematically discovering the physiological and behavioral functions of genes to identify potential points of therapeutic intervention, or drug targets. We make these discoveries using our proprietary technology to knock out, or disrupt, the function of genes in mice. Our gene knockout technology allows us to model, on a genome-wide scale, the effects on physiology that could be expected from prospective drugs directed against novel targets. For targets that we believe have high pharmaceutical value, we engage in programs for the discovery and development of small molecule drugs, therapeutic antibodies and therapeutic proteins. We have advanced more than 70 knockout-validated targets into drug discovery programs in six therapeutic areas: diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. Our physiology-based approach to understanding gene function and our use of knockouts to model expected drug action are designed to identify new ways to treat major human diseases. We are using our proprietary gene knockout technology in our Genome5000™ program to rapidly discover the functions of the most pharmaceutically important genes in the human genome - 5,000 genes that have desirable characteristics for pharmaceutical development. To date, we have completed our analysis of more than one third of these genes. We believe our unique ability to systematically determine the physiological and behavioral function of genes provides us with a strategic advantage in the race to discover future breakthrough therapeutics. We are working both independently and through strategic collaborations and alliances to accelerate the development and commercialization of our discoveries. We have formed a broad alliance with Bristol-Myers Squibb for drug discovery, development and commercialization in the neuroscience field. We are working with Genentech, Inc. to discover the functions of secreted proteins and potential antibody targets identified through Genentech's internal drug discovery research. We are collaborating with Organon to jointly discover, develop and commercialize novel biotherapeutics. We have established an alliance with Takeda Pharmaceutical Company Limited to accelerate the development and commercialization of new drugs for the treatment of high blood pressure. We have also established numerous other collaborations with leading pharmaceutical and biotechnology companies, as well as research and academic institutions. back to top

Contact Us | Terms of Use | Site Map | Search | Home Copyright © 2005, Lexicon Genetics Incorporated. All rights reserved.